Reduced expression levels of the cell-cycle inhibitor p27(Kip)1 in human pituitary adenomas

European Journal of Endocrinology

Volumn 140, Issue 3, 1999, Pages 250-255

  Bamberger, Christoph M ^a,b   Fehn, Marita ^c   Bamberger, Ana Maria ^a,b   Lüdecke, Dieter K ^b   Beil, Frank Ulrich ^b   Saeger, Wolfgang ^c   Schulte, Heinrich M ^a  

^a UNIVERSITY OF HAMBURG   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c Marienkrankenhaus Hamburg ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; PROOPIOMELANOCORTIN; PROTEIN P27; REGULATOR PROTEIN;

ARTICLE; CELL CYCLE PHASE; CELL PROLIFERATION; CONTROLLED STUDY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOPHYSIS ADENOMA; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ASSAY;

EID: 0032946006     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1400250     Document Type: Article

References (39)

1. Shimon I & Melmed S. Pituitary tumor pathogenesis. Journal of Clinical Endocrinology and Metabolism 1997 82 1675-1681.
2. Alexander JM, Biller BMK, Bikkal H, Zervas NT, Arnold A & Klibanski A. Clinically nonfunctioning pituitary adenomas are monoclonal in origin. Journal of Clinical Investigation 1990 86 336-340.
3. Herman V, Fagin J, Gonsky R, Kovacs K & Melmed S. Clonal origin of pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 1990 71 1427-1433.
4. Schulte HM, Oldfield EH, Allolio B, Katz DA, Berkman RA & Ali IU. Clonal composition of pituitary adenomas in patients with Cushing's disease: determination by X-chromosome inactivation analysis. Journal of Clinical Endocrinology and Metabolism 1991 73 1302-1308.
5. Biller BMK, Alexander JM, Zervas NT, Hedley-White ET, Arnold A & Klibanski A. Clonal origins of adrenocorticotropin-secreting pituitary tissue in Cushing's disease. Journal of Clinical Endocrinology and Metabolism 1992 75 1303-1309.
6. Gicquel C, Le Bouc Y, Luton J-P, Girard F & Bertagna X. Monoclonality of corticotroph macroadenomas in Cushing's disease. Journal of Clinical Endocrinology and Metabolism 1992 75 472-475.
7. Landis CA, Masters SB, Spada A, Pace AM, Bourne HR & Vallar L. GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumours. Nature 1989 340 692-696.
8. Clementi E, Malgaretti N, Meldolesi J & Taramelli R. A new constitutively activating mutation of the Gs protein alpha subunit-gsp oncogene is found in human pituitary tumours. Oncogene 1990 5 1059-1061.
9. Lyons J, Landis CA, Harsh G, Vallar L, Grünewald K, Feichtinger H et al. Two G protein oncogenes in human endocrine tumors. Science 1990 249 655-659.
10. Boggild MD, Jenkinson S, Pistorello M, Boscaro M, Scanarini M, McTernan P et al. Molecular genetic studies of sporadic pituitary tumors. Journal of Clinical Endocrinology and Metabolism 1994 78 387-392.
11. Tordjman K, Stern N, Ouaknine G, Yossiphov Y, Razon N, Nordenskjöld M et al. Activating mutations of the Gs alpha-gene in nonfunctioning pituitary tumors. Journal of Clinical Endocrinology and Metabolism 1993 77 765-769.
12. Williamson EA, Ince PG, Harrison D, Kendall-Taylor P & Harris PE. G-protein mutations in human pituitary adrenocorticotrophic hormone-secreting adenomas. European Journal of Clinical Investigation 1995 25 128-131.
13. Sherr CJ & Roberts JM. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes and Development 1995 9 1149-1163.
14. Morgan DO. Principles of CDK regulation. Nature 1995 374 131-134.
15. Hunter T & Pines J. Cyclins and cancer. II: cyclin D and CDK inhibitors come of age. Cell 1994 79 573.
16. Catzavelos C, Bhattacharya N, Ung YC, Wilson JA, Roncari L, Sandhu C et al. Decreased levels of the cell-cycle inhibitor p27/ KIP1 protein: prognostic implications in primary breast cancer. Nature Medicine 1997 3 227-230.
17. Loda M, Cukor B, Tam SW, Lavin P, Florentino M, Draetta GF et al. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal cancers. Nature Medicine 1997 3 231-234.
18. Polyak K, Lee M-H, Erdjument-Bromage H, Koff A, Roberts JM, Tempst P et al. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and potential mediator of extracellular antimitogenic signals. Cell 1994 78 59-66.
19. Toyoshima H & Hunter T. p27, a novel inhibitor of G1 cyclin-cdk protein kinase activity, is related to p21. Cell 1994 78 67-74.
20. kip1) of cyclin-dependent kinase 4 activation. Cell 1994 79 487-496.
21. Nourse J, Firpo E, Flanagan WM, Coats S, Polyak K, Lee M et al. Interleukin-2-mediated elimination of the p27KIP1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature 1994 372 570-573.
22. Polyak K, Kato J, Solomon MJ, Sherr CJ, Massague J, Roberts JM et al. p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-β and contact inhibition to cell cycle arrest. Genes and Development 1994 8 9-22.
23. Reynisdottir I, Polyak K, Iavarone A & Massague J. Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta. Genes and Development 1995 9 1831-1845.
24. Kip1-deficient mice. Cell 1996 85 733-744.
25. Kip1. Cell 1996 85 721-732.
26. Kip1 display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 1996 85 707-720.
27. Bamberger AM, Schulte HM, Thuneke I, Erdmann I, Milde-Langosch K, Riethdorf L et al. Strongly reduced or abolished expression of the cell cycle inhibitor p27 in endometrial cancer. Virchow's Archives 1999 (In Press).
28. Karga HJ, Alexander JM, Hedley-Whyte ET, Klibanski A & Jameson JL. ras mutations in human pituitary tumors. Journal of Clinical Endocrinology and Metabolism 1992 74 914-919.
29. Cryns VL, Alexander JM, Klibanski A & Arnold A. The retinoblastoma gene in human pituitary tumors. Journal of Clinical Endocrinology and Metabolism 1993 77 644-646.
30. Levy A, Hall L, Yeudall WA & Lightman SL. p53 gene mutations in pituitary adenomas: rare events. Clinical Endocrinology 1994 41 809-814.
31. Kip1 expression in nontumorous and neoplastic human pituitaries. American Journal of Pathology 1997 151 509-519.
32. Ikeda H, Yoshimoto T & Shida N. Molecular analysis of p21 and p27 genes in human pituitary adenomas. British Journal of Cancer 1997 76 1119-1123.
33. Kip1 gene and trisomy 12 in a subset of human pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 1997 82 3141-3147.
34. Dahia PLM, Aguiar RCT, Honegger J, Fahlbusch R, Jordan S, Lowe DG et al. Mutation and expression analysis of p27/kip1 gene in corticotrophin-secreting tumours. Oncogene 1998 16 69-76.
35. Kawamata N, Morosetti R, Miller CW, Park D, Spirin KS, Nakamaki T et al. Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in human malignancies. Cancer Research 1995 55 2266-2269.
36. Ponce-Castaneda MV, Lee M-H, Latres E, Polyak K, Lacombe L, Montgomery K et al. p27/Kip1: chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumors. Cancer Research 1995 55 1211-1214.
37. Pagano M, Tam SW, Theodorras AM, Beer-Romero P, Del Sal G, Chau V et al. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 1995 269 682-685.
38. Ezzat S, Walpola IA, Ramyar L, Smyth HS & Asa SL. Membrane-anchored expression of transforming growth factor-alpha in human pituitary adenoma cells. Journal of Clinical Endocrinology and Metabolism 1995 80 534-539.
39. McAndrew J, Paterson AJ, Asa SL, McCarthy KJ & Kudlow JE. Targeting of transforming growth factor-alpha expression to pituitary lactotrophs in transgenic mice results in selective lactotroph proliferation and adenomas. Endocrinology 1995 136 4479-4488.